Global Alliance for TB Drug Development

TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB). Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. 

With an annual operating budget of approximately $60 million, the TB Alliance leads the advancement of the most comprehensive R&D portfolio of TB drug candidates in history. Currently, a portfolio of more than 20 projects spans from target validation to Phase III clinical development. Additionally, the TB Alliance drives efforts to ensure regulatory approval, country adoption of new regimens, and widespread availability of new drug regimens to patients.

Tuberculosis kills nearly 1.5 million each year. Yet, current treatments are antiquated, inadequate, and excessively burdensome. Long, demanding treatment schedules prove too much for many patients, leading to the emergence of multi- and extensively- drug-resistant TB (MDR-TB and XDR-TB), which are exponentially more expensive and difficult to treat.

For more information, please access the website: www.tballiance.org.